Company Overview


Mariposa Health is a pharmaceutical development company specializing in; It has two products that have completed initial Phase 2 clinical trials in the field of chronic obstructive pulmonary disorder (COPD) and asthma. One of our products is ready to commence Phase 2 clinical trials for the treatment of Allergic Rhinitis. After developing initial IP on the use of a vaccine to Golden staph to reduce respiratory sleep conditions, Mariposa Health then grew through acquisition; Mariposa Health has completed a deal with Shanxi Kangbao Biological Product Co., of the PR China, for the exclusive rights to develop and commercialize HI-164 in the PR China and its territories. Mariposa Health is now well positioned for its next phase or consolidation and growth.